Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has provided an update.
MaxCyte, Inc. has announced a change in the voting rights held by BlackRock, Inc., a major shareholder. BlackRock’s voting rights in MaxCyte have increased to 8.24% from a previous 7.90%, indicating a significant acquisition of shares and financial instruments. This adjustment in holdings may influence MaxCyte’s strategic decisions and reflects BlackRock’s growing interest in the company’s potential within the biotechnology sector.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, providing cell-engineering platform technologies that enable the development and commercialization of next-generation cell-based therapies. The company focuses on enhancing the capabilities of its partners in the development of innovative medical treatments.
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.